CA2986687A1 - Fabrication de vaccins multidoses prets a injecter a base de cellules dendritiques - Google Patents

Fabrication de vaccins multidoses prets a injecter a base de cellules dendritiques

Info

Publication number
CA2986687A1
CA2986687A1 CA2986687A CA2986687A CA2986687A1 CA 2986687 A1 CA2986687 A1 CA 2986687A1 CA 2986687 A CA2986687 A CA 2986687A CA 2986687 A CA2986687 A CA 2986687A CA 2986687 A1 CA2986687 A1 CA 2986687A1
Authority
CA
Canada
Prior art keywords
cells
cancer
antigen
dendritic cell
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2986687A
Other languages
English (en)
Inventor
Brian J. Czerniecki
Gary K. Koski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2015/041022 external-priority patent/WO2016011422A2/fr
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of CA2986687A1 publication Critical patent/CA2986687A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast

Abstract

Les présents modes de réalisation concernent un vaccin injectable multidose approuvé par la FDA à base de cellules dendritiques (CD) à impulsions antigéniques. Dans un mode de réalisation, le vaccin à base de CD chargées d'antigènes activés comprend une dose d'immunisation initiale et plusieurs doses de rappel. L'invention concerne également un procédé de traitement permettant d'inhiber à la fois HER-2 et HER-3, ce qui provoque une sénescence permanente de la tumeur dans les cancers du sein exprimant HER-2. L'invention concerne également un traitement combiné associant thérapie anti-strogénique et vaccination anti-HER2 à base de cellules dendritiques pour les patients atteints d'un cancer du sein de type carcinome canalaire in situ ERpos/HER2pos.
CA2986687A 2015-05-22 2016-03-05 Fabrication de vaccins multidoses prets a injecter a base de cellules dendritiques Pending CA2986687A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562165445P 2015-05-22 2015-05-22
US62/165,445 2015-05-22
WOPCT/US2015/041022 2015-07-17
PCT/US2015/041022 WO2016011422A2 (fr) 2014-07-17 2015-07-17 Fabrication de vaccins à base de cellules dendritiques multi-doses prêts à être injectés, et polythérapie pour bloquer her2 et her3
PCT/US2016/021090 WO2016190940A1 (fr) 2015-05-22 2016-03-05 Fabrication de vaccins multidoses prêts à injecter à base de cellules dendritiques

Publications (1)

Publication Number Publication Date
CA2986687A1 true CA2986687A1 (fr) 2016-12-01

Family

ID=57393543

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2986687A Pending CA2986687A1 (fr) 2015-05-22 2016-03-05 Fabrication de vaccins multidoses prets a injecter a base de cellules dendritiques

Country Status (5)

Country Link
EP (1) EP3302539A4 (fr)
JP (2) JP2018515421A (fr)
CN (1) CN107206061A (fr)
CA (1) CA2986687A1 (fr)
WO (1) WO2016190940A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016011347A1 (fr) * 2014-07-17 2016-01-21 The Trustees Of The University Of Pennsylvania Vaccins à base de cellules dendritiques multi-doses prêts à être injectés, et polythérapie anticancéreuse
WO2019103151A1 (fr) * 2017-11-27 2019-05-31 国立大学法人千葉大学 Structure membranaire lipidique pour distribuer un acide nucléique dans une cellule

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
DE10041515A1 (de) * 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
WO2003012085A1 (fr) * 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Cellules presentant l'antigene, procede de preparation et d'utilisation dans les vaccins contre le cancer
CA2504451A1 (fr) * 2004-08-10 2006-02-10 Geron Corporation Vaccins a cellules dendritiques faits de cellules souches embryonnaires pour le traitement du cancer
US8247227B2 (en) * 2006-08-28 2012-08-21 The Cleveland Clinic Foundation Dendritic cell precursors
JP2013522309A (ja) * 2010-03-15 2013-06-13 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 活性化した成熟樹状細胞を調製し保存するシステムおよび方法
CA2823540A1 (fr) * 2010-12-30 2012-07-05 Anthrogenesis Corporation Procedes de cryoconservation et d'encapsulation de cellules
EP2548571A1 (fr) * 2011-07-22 2013-01-23 Institut Curie Compositions dotées de supports de ciblage d'au moins un antigène sur des cellules dendritiques
EP3129034A4 (fr) * 2014-03-14 2017-11-22 Brian J. Czerniecki Méthodes de suivi de la réponse lymphocytaire impliquant des lymphocytes t auxiliaires cd4+ de type 1 dans le cancer et la reconstitution immunitaire
WO2016011347A1 (fr) * 2014-07-17 2016-01-21 The Trustees Of The University Of Pennsylvania Vaccins à base de cellules dendritiques multi-doses prêts à être injectés, et polythérapie anticancéreuse
CA2979676A1 (fr) * 2015-03-13 2016-09-29 Brian J. Czerniecki Methodes de suivi de la reponse lymphocytaire impliquant des lymphocytes t auxiliaires cd4+ de type 1 dans le cancer et la reconstitution immunitaire
JP2018510644A (ja) * 2015-03-26 2018-04-19 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 治療およびエピトープマッピング用Ｔ細胞の感作および増殖のためのｉｎ ｖｉｔｒｏ人工リンパ節
US20180171294A1 (en) * 2015-03-26 2018-06-21 The Trustees Of The University Of Pennsylvania In vitro artificial lymph node method for sensitization and expansion of t cells for therapy and epitope mapping

Also Published As

Publication number Publication date
EP3302539A4 (fr) 2018-12-19
EP3302539A1 (fr) 2018-04-11
JP2020180139A (ja) 2020-11-05
WO2016190940A1 (fr) 2016-12-01
CN107206061A (zh) 2017-09-26
JP2018515421A (ja) 2018-06-14

Similar Documents

Publication Publication Date Title
US20170216421A1 (en) Manufacturing of multi-dose injection ready dendritic cell vaccines, combination therapies for blocking her2 and her3, and estrogen receptor positive her2 breast receptor positive her2 breast cancer therapy
US20210292433A1 (en) Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
US20210207148A1 (en) Synthetic rig-i-like receptor agonists
JP2022092001A (ja) 樹状細胞免疫療法
US20220125835A1 (en) Silicified immunogenic cells, methods of making, and methods of using
JP2020180139A (ja) 複数用量注射準備済樹状細胞ワクチンの製造
JP2020169178A (ja) 複数用量注射準備済樹状細胞ワクチンの製造ならびにｈｅｒ２およびｈｅｒ３を遮断するための併用療法
Xu et al. High-avidity antitumor T-cell generation by toll receptor 8–primed, myeloid-derived dendritic cells is mediated by IL-12 production
CA3023245A1 (fr) Peptides cibles pour le traitement et le diagnostic du cancer
Kobukai et al. Induction of antitumor immunity by dendritic cells loaded with membrane-translocating mucin 1 Peptide antigen
AU2019203111B2 (en) Manufacturing of multi-dose injection ready dendritic cell vaccines, combination therapies for blocking HER2 and HER3, and estrogen receptor positive HER2 breast cancer therapy
WO2012101109A1 (fr) Cellules dendritiques natives
US20220401535A1 (en) Hyperactive Dendritic Cells Enable Durable Adoptive Cell Transfer-Based Anti-Tumor Immunity
JP2024503278A (ja) 修飾ｐｂｍｃを用いたがんの治療方法
Park et al. Protein cage nanoparticle-based NK cell-engaging nanodrones (NKeNDs) effectively recruit NK cells to target tumor sites and suppress tumor growth
JP5084012B2 (ja) イディオタイプ抗原用担体およびそれを用いたイディオタイプワクチン
CN116917319A (zh) 用于用经修饰的pbmc治疗癌症的方法
Meini Antitumor activity of locoregional combined CpG-ODN therapy in experimental carcinoma models
Grant Efficacy of B16OVA Tumour Cell Lysate Conjugated to Rabbit Haemorrhagic Disease Virus Virus-Like Particles as an Anti-Tumour Vaccine
Brown An empirical framework for combining surgery with immune therapy
CLERICI SCUOLA DI DOTTORATO IN MEDICINA MOLECOLARE

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210304

EEER Examination request

Effective date: 20210304

EEER Examination request

Effective date: 20210304

EEER Examination request

Effective date: 20210304

EEER Examination request

Effective date: 20210304

EEER Examination request

Effective date: 20210304